Bradykinin and cardioprotection: Don't set your heart on it

Pharmacological Research

Volumn 35, Issue 6, 1997, Pages 531-536

  Hatta, Eiichiro ^a   Rubin, Lisa E ^a   Seyedi, Nahid ^a   Levi, Roberto ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ;

ADRENERGIC ACTIVITY; ANAPHYLAXIS; ARTICLE; CORONARY ARTERY DILATATION; HEART PROTECTION; PRIORITY JOURNAL;

EID: 0031172656     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1997.0182     Document Type: Article

References (53)

1. 1. JR Parratt. Cardioprotection by angiotensin converting enzyme inhibitors - The experimental evidence. Cardiovasc Res 1994; 28: 183-9.
2. 2. W Linz, G Wiemer, P Gohlke, T Unger, BA Schölkens. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
3. 3. YM Pinto, H Buikema and WH Van Gilst. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: Experimental evidence and clinical hypotheses. Clin Exp Hypertens 17: 441-68 (1995).
4. 4. W Linz, G Wiemer and BA Schölkens. Role of kinins in the pathophysiology of myocardial ischaemia - in vitro and in vivo studies. Diabetes 1996; 45 Suppl 1: S51-8.
5. 5. JC Hartman. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. Ann Thorac Surg 60: 789-92 (1995).
6. 6. B Hornig, C Kohler and H Drexler. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-18.
7. 7. JH Schwieler and P Hjemdahl. Influence of angiotensin-converting enzyme inhibition on sympathetic neurotransmission: possible roles of bradykinin and prostaglandins. J Cardiovasc Pharmacol 1992; 20 Suppl 9: S39-46.
8. 8. LC Rump, C Bohmann, U Schaible, W Schultze-Seemann and PJ Schollmeyer, β-Adrenergic, angiotensin II and bradykinin receptors enhance neurotransmission in human kidney. Hypertension 1995; 26: 445-51.
9. 9. M Vaz-da-Silva, S Magina, A Domingues-Costa, D Moura and S Guimaraes. The role of the endocardium in the facilitatory effect of bradykinin on electrically-induced release of noradrenaline in rat cardiac ventricle. Br J Pharmacol 1996; 118: 364-8.
10. 10. RD Minshall, VP Yelamanchi, A Djokovic, D J Miletich, EG Erdös, SF Rabito and SM Vogel. Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res 1994; 74: 441-7.
11. 11. C Chulak, R Couture and S Foucart. Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria. Br J Pharmacol 1995; 115: 330-4.
12. 2 receptors. Pflugers Arch 1996; 432 Suppl R99-106.
13. 13. LE Rubin and R Levi. Protective role of bradykinin in cardiac anaphylaxis: coronary-vasodilating and antiarrhythmic activities mediated by autocrine/ paracrine mechanisms. Circ Res 1995; 76: 434-40.
14. 14. M Imamura and R Levi. Bradykinin promotes exocytotic and carrier-mediated norepinephrine release in myocardial ischaemia-reperfusion. Circulation 1995; 92: 1-568.
15. 15. N Seyedi and R Levi. Bradykinin facilitates norepinephrine exocytosis from cardiac sympathetic nerve endings. FASEB J 1996; 3: A695.
16. 16. KH Park, LE Rubin, SS Gross and R Levi. Nitric oxide is a mediator of hypoxic coronary vasodilatation: relation to adenosine and cyclooxygenase-derived metabolites. Circ Res 1992; 71: 992-1001.
17. 17. FJ Hock, K Wirth, U Albus, W Linz, HJ Gerhards, G Wiemer, S Henke, G Breipohl, W Konig, J Knolle and B A Schölkens. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991; 102: 769-73.
18. 18. NE Rhaleb, G Drapeau, S Dion, D Jukic, N Rouissi and D Regoli. Structure-activity studies on bradykinin and related peptides: agonists. Br J Pharmacol 1990; 99: 445-8.
19. 19. I Sakuma, DJ Stuehr, SS Gross, C Nathan and R Levi, Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988; 85: 8664-7.
20. 20. WT Beraldo. Formation of bradykinin in anaphylactic and peptone shock. Am J Physiol 1950; 163: 283-9.
21. 21. WE Brocklehurst and SC Lahiri. The production of bradykinin in anaphylaxis. J Physiol 1962; 160: P15-6.
22. 22. PL Smith, A Kagey-Sobotka, ER Bleecker, R Traystam, AP Kaplan, H Gralnick, MD Valentine, S Permutt and LM Lichtenstein. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66: 1072-80.
23. 23. D Proud, A Togias, RM Naclerio, SA Crush, P S Norman and LM Lichtenstein. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983; 72: 1678-85.
24. 24. R Levi. Cardiac anaphylaxis: models, mediators, mechanisms and clinical considerations. In: G Marone, LM Lichtenstein, M Condorelli, AS Fauci, eds Human Inflammatory Disease, Clinical Immunology. Toronto, Canada: BC Decker, 1988: 93-105.
25. 25. DJ Cooper. Cardiac dysfunction during anaphylaxis in patients. ACP 1993; 5: 9-18.
26. 26. JM Stewart, L Gera, W Hanson, JS Zuzack, M Burkard, R McCullough and ET Whalley, A new generation of bradykinin antagonists. Immunopharmacology 1996; 33: 51-60.
27. 27. AT Chiu, WF Herblin, DE McCall, RJ Ardecky, D J Carini, JV Duncia, LJ Pease, PC Wong, RR Wexler, AL Johnson et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 1989; 165: 196-203.
28. 28. JW Ryan, US Ryan, DR Schultz, C Whitaker and A Chung. Subcellular localization of pulmonary antiotensin-converting enzyme (kininase II). Biochem J 1975; 146: 497-9.
29. 29. G Wiemer, BA Schölkens, RH A Becker and R Busse, Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-63.
30. 30. H Nolly, OA Carretero and AG Scicli. Kallikrein release by vascular tissue. Am J Physiol Heart Circ Physiol 1993; 265: H1209-14.
31. 31. AH Schmaier, A Kuo, D Lundberg, S Murray and D B Cines. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988; 31: 16327.
32. 32. KD Bhoola, CD Figueroa and K Worthy. Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol Rev 1992; 44: 1-80.
33. 33. D Lamontagne, U Pohl and R Busse. Mechanical deformation of vessel wall and shear stress determine the basal release of endothelium-derived relaxing factor in the intact rabbit coronary vascular bed. Circ Res 1992; 70: 123-30.
34. 34. PM Vanhoutte, CM Boulanger, SC Illiano, T Nagao, M Vidal and J-V Mombouli. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993; 22 Suppl 5: S10-6.
35. 2+]. in aortic endothelium. J Cell Physiol 1992; 151: 37-40.
36. 36. R Busse, M Hecker and I Fleming. Control of nitric oxide and prostacyclin synthesis in endothelial cells. Arzneimittelforschung. 1994; 44: 392-6.
37. 37. G Wiemer, BA Schölkens and W Linz. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 1994; 28: 166-72.
38. 38. W Auch-Schwelk, C Bossaller, M Claus, K Graf, M Graefe and E Fleck, ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993; 27: 312-17.
39. 39. M Hecker, I Pörsti, AT Bara and R Busse. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol 1994; 111: 238-44.
40. 40. HH Newball, RW Berninger, RC Talamo and L M Lichtenstein. Anaphylactic release of a basophil kallikrein-like activity. I. Purification and characterization. J Clin Invest 1979; 64: 457-465.
41. 41. HL Nolly, G Saed, G Scicli, OA Carretero and A G Scicli. The kallikrein-kinin system in cardiac tissue. Agents Actions Suppl 1992; 38: 62-72.
42. 42. W Kübler and RH Strasser. Signal transduction in myocardial ischaemia. Eur Heart J 1994; 15: 437-445.
43. 43. CR Benedict, B Shelton, DE Johnstone, G Francis, B Greenberg, M Konstam, JL Probstfield and S Yusuf, Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-7.
44. 44. A Schömig, M Haass and G Richardt. Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur Heart J 1991; 12 (SupplF): 38-47.
45. 3 receptors in myocardial ischaemia: their role as regulators of exocytotic norepinephrine release. J Pharmacol Exp Ther 1994; 271: 1259-66.
46. 46. E Kimura, K Hashimoto, S Furukawa and H Hayakawa, Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J 1973; 85: 635-47.
47. 47. T Matsuki, T Shoji and S Yoshida. Sympathetically induced myocardial ischaemia causes the heart to release plasma kinin. Cardiovasc Res 1987; 21: 428-32.
48. 9-bradykinin release following reperfusion of the ischaemic rat heart. Br J Pharmacol 1995; 115: 476-8.
49. 49. IJ Zeitlin, SO Fagbemi and JR Parratt. Enzymes in normally perfused and ischaemic dog hearts which release a substance with kinin like activity. Cardiovasc Res 1989; 23: 91-7.
50. 50. K Arakawa. Presidential lecture - Serine protease angiotensin II systems. J Hypertens 1996; 14 Suppl 5: S3-7.
51. 2-adrenoceptors. Circ Res 1996; 78: 475-81.
52. 52. A Schömig. Catecholamines in myocardial ischaemia. Systemic and cardiac release. Circulation 1990; 82: 13-22.
53. 53. AM Dart and X-J Du. Unexpected drug effects on autonomie function during myocardial ischaemia. Cardiovasc Res 1993; 27: 906-14.